Quarterly report pursuant to Section 13 or 15(d)

FAIR VALUE OF FINANCIAL INSTRUMENTS (Tables)

v3.24.2
FAIR VALUE OF FINANCIAL INSTRUMENTS (Tables)
 3 Months Ended
Mar. 31, 2024
Fair Value Disclosures [Abstract]  
SCHEDULE OF FAIR VALUE, LIABILITIES MEASURED ON RECURRING BASIS

As of March 31, 2024 and December 31, 2023, we had contingent consideration that is required to be measured at fair value on a recurring basis.

Our financial instruments measured at fair value on a recurring basis were as follows at the dates indicated:

 

      Level 1     Level 2     Level 3     Total  
    Condensed Consolidated
Balance Sheet Caption		   Fair Value at March 31, 2024  
(in thousands)       Level 1     Level 2     Level 3     Total  
Liabilities:                                    
Contingent consideration - current   Accrued expenses and other current liabilities   $ —     $ —       1,000       1,000  
Total Liabilities       $ —     $ —     $ 1,000     $ 1,000  

 

(in thousands)       Level 1     Level 2     Level 3     Total  
    Condensed Consolidated
Balance Sheet Caption		   Fair Value at December 31, 2023  
(in thousands)       Level 1     Level 2     Level 3     Total  
Liabilities:                                    
Contingent consideration - current   Accrued expenses and other current liabilities   $ —     $ —       1,000       1,000  
Total Liabilities       $ —     $ —     $ 1,000     $ 1,000  
SCHEDULE OF FAIR VALUE, LIABILITIES MEASURED ON RECURRING BASIS, UNOBSERVABLE INPUT RECONCILIATION

A reconciliation of our liabilities that are measured and recorded at fair value on a recurring basis using significant unobservable inputs (Level 3) is as follows:

 

  

(in thousands)  

Three Months Ended

March 31, 2024

  
Balance at December 31, 2023   $ 1,000  
Cash payments for earned contingent consideration     —  
Transfer to notes payable     —  
Loss (gain) from fair value adjustments included in results of operations     —  
Balance March 31, 2024   $ 1,000